tetano
Editor, Senior Moderator
Nat Rev Immunol
. 2022 Dec 20.
doi: 10.1038/s41577-022-00809-x. Online ahead of print.
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
Sam M Murray[SUP] 1 [/SUP], Azim M Ansari[SUP] 1 [/SUP], John Frater[SUP] 1 2 3 [/SUP], Paul Klenerman[SUP] 1 2 3 [/SUP], Susanna Dunachie[SUP] 1 2 3 4 5 [/SUP], Eleanor Barnes[SUP] 6 7 8 [/SUP], Ane Ogbe[SUP] 9 [/SUP]
Affiliations
Abstract
Pre-existing cross-reactive immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by several studies. In particular, regions of high homology between SARS-CoV-2 and common cold coronaviruses have been highlighted as a likely source of this cross-reactivity. However, the role of such cross-reactive responses in the outcome of SARS-CoV-2 infection and vaccination is currently unclear. Here, we review evidence regarding the impact of pre-existing humoral and T cell immune responses to outcomes of SARS-CoV-2 infection and vaccination. Furthermore, we discuss the importance of conserved coronavirus epitopes for the rational design of pan-coronavirus vaccines and consider cross-reactivity of immune responses to ancestral SARS-CoV-2 and SARS-CoV-2 variants, as well as their impact on COVID-19 vaccination.
. 2022 Dec 20.
doi: 10.1038/s41577-022-00809-x. Online ahead of print.
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
Sam M Murray[SUP] 1 [/SUP], Azim M Ansari[SUP] 1 [/SUP], John Frater[SUP] 1 2 3 [/SUP], Paul Klenerman[SUP] 1 2 3 [/SUP], Susanna Dunachie[SUP] 1 2 3 4 5 [/SUP], Eleanor Barnes[SUP] 6 7 8 [/SUP], Ane Ogbe[SUP] 9 [/SUP]
Affiliations
- PMID: 36539527
- DOI: 10.1038/s41577-022-00809-x
Abstract
Pre-existing cross-reactive immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by several studies. In particular, regions of high homology between SARS-CoV-2 and common cold coronaviruses have been highlighted as a likely source of this cross-reactivity. However, the role of such cross-reactive responses in the outcome of SARS-CoV-2 infection and vaccination is currently unclear. Here, we review evidence regarding the impact of pre-existing humoral and T cell immune responses to outcomes of SARS-CoV-2 infection and vaccination. Furthermore, we discuss the importance of conserved coronavirus epitopes for the rational design of pan-coronavirus vaccines and consider cross-reactivity of immune responses to ancestral SARS-CoV-2 and SARS-CoV-2 variants, as well as their impact on COVID-19 vaccination.